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tients with atrial fibrillation (AF). Recently, non-vitamin K antagonist oral anticoagulants
(NOACs) have been approved as an alternative to warfarin in nonvalvular AF. However, there
is a limited amount of real-world data on how NOACs are currently being used in Taiwan. This
study was conducted to investigate the factors driving the initiation of anticoagulants and the
selection of different anticoagulants in patients with AF.
Methods: We used National Taiwan University Hospital’s electronic database to identify all
nonvalvular AF patients from January 1, 2007 to December 31, 2013. Multivariate logistic
regression models were used to examine the factors driving the initiation of anticoagulants
and the selection of different anticoagulants.
Results: Among AF patients, 66.4% of anticoagulants users used NOACs instead of warfarin af-
ter the era of NOACs. Patients with female sex, hypertension, ischemic heart disease, cancer,
hepatic disease, renal disease, bleeding history, and aspirin use were less likely to be antico-
agulant users but are more likely to be anticoagulant users with a history of stroke (odds
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patients with atrial fibrillation, Jouraspirin use were the factors associated with NOACs usage, whereas hepatic disease showed the
opposite results (odds ratio Z 0.09; 95% confidence interval, 0.02e0.42).
Conclusion: Stroke history was associated with anticoagulant use, whereas comorbidities asso-
ciated with increased risk of bleeding showed the opposite result. Patients with hepatic dis-
ease were less likely to use NOACs.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Atrial fibrillation (AF) is a common arrhythmia encountered
in clinical practice. Stroke is one of the complications of AF,
which results in serious disability and increased economic
burden for patients and their families. In the past, warfarin
was the drug of choice for stroke prevention in AF patients,
especially for those at higher risk.1 However, reports
showed underuse of warfarin.2,3 Nearly 28% of AF patients
received warfarin in the Taiwan Stroke Registry from 2006
to 2008.4 Only 24.7% of AF patients received appropriate
antithrombotic therapy according to treatment guideline in
a study performed using the National Health Insurance
Research Database (NHIRD) between 2003 and 2004.5
Non-vitamin K antagonist oral anticoagulants (NOACs),
including dabigatran, rivaroxaban, apixaban, and edox-
aban, have shown more encouraging efficacy and safety
profiles compared to warfarin.6e10 Current treatment
guidelines suggest NOACs as alternatives to warfarin in
nonvalvular AF.11,12 Some reports from Denmark have
explored the use of NOACs and factors associated with the
use of NOACs after they were approved for release on the
market.13,14 Since 2012, NOACs have been available in
Taiwan. So far, there is limited real-world data on how
NOACs are currently being used as well as factors driving
the initiation and selection of anticoagulants. The objec-
tive of our study is to investigate factors driving the initi-
ation of anticoagulants (anticoagulant vs. no anticoagulant)
and the selection of different anticoagulants (warfarin or
NOACs) in Taiwan.Methods
Data source
We used National Taiwan University Hospital’s (NTUH)
electronic database from 2006 to 2013 as our data source.
NTUH is a 2500-bed tertiary medical center that serves 2000
inpatients and 8000 outpatients daily. The database pro-
vides information from outpatient, inpatient, and emer-
gency departments with the disease diagnosis according to
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes as well as surgery
and procedure records for the patients. All prescription
records are available from the pharmacy department. Using
specified identification code for each patient, all informa-
tion can be linked together. Our study was approved by the
institutional review board of the NTUH.M-M, et al., Factors driving the u
nal of the Formosan Medical AssoStudy design
We first identified newly diagnosed AF patients from 2007
to 2013. Newly diagnosed was defined as no AF disease
codes (ICD-9-CM code 427.31) present in the database from
outpatient, inpatient, or emergency department in 2006.
Patients with at least three AF disease codes from January
1, 2007 to December 31, 2013 were recruited into study.
Individuals with no age record or younger than 20 years
were excluded. Patients with valvular AF (history of rheu-
matic heart disease, or had undergone valve repair or
replacement), history of pulmonary embolism or deep vein
thrombosis, or had undergone hip or knee replacement
within 1 year prior to study entry were excluded. Antico-
agulant users were grouped according to the first antico-
agulant prescription record after AF was first diagnosed.
Dabigatran (110 mg; available since February 1, 2013) and
rivaroxaban (20 mg; available since November 1, 2013)
were the two available NOACs during the study period. For
patients with no anticoagulant treatment throughout study,
the date when AF was first diagnosed served as their index
date. The date of the first anticoagulant prescription was
defined as the index date for anticoagulant users.
Definition for variables
Records related to comorbidities, surgeries, and concomi-
tant medications were collected within 12 months prior to
the index date. Comorbidities were defined as ICD-9-CM
codes present in the hospital database within 1 year prior to
the index date. The ICD-9-CM codes used in our study are
shown in Appendix 1. Information related to valve repair,
valve replacement, and hip or knee replacement were
defined using the codes for surgery and physician orders
provided by the Information Technology Center from NTUH.
The codes are listed in Appendix 2. Generic names for
concomitant medications used in the study are given in
Appendix 3. The CHADS2 score indicates congestive heart
failure, hypertension, age 75 years, diabetes mellitus,
prior stroke or TIA (transient ischemic attack) or TE
(thromboembolism) score; CHA2DS2-VASc score for conges-
tive heart failure, hypertension, age 75 years, diabetes
mellitus, prior stroke or TIA or TE, vascular disease, age
65e74 years, sex category point score systems; HAS-BLED
score for hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile INR (in-
ternational normalized ratio), age older than 65 years,
concomitant use of drugs or alcohol. Calculations for the
scoring systems mentioned above were made usingse of warfarin and non-vitamin K antagonist oral anticoagulants in
ciation (2016), http://dx.doi.org/10.1016/j.jfma.2016.05.007
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1 and 3. We also collected INR values and alcohol use
from social history. Labile INR and alcohol use were not
calculated in HAS-BLED score because some patients had
missing data. Patients who had their first anticoagulant
prescription in 2013 were analyzed to provide information
on warfarin versus NOAC use after the introduction of
NOACs to NTUH. Data were presented using total patient
number of first anticoagulant initiation and the percentage
of warfarin and NOAC use in each month.Table 1 Patient demographics.
Variables Total patient
(n Z 3662)
No anticoagula
treatment
(n Z 2447)
Age, mean (SD) 69.9 (12.8) 70.3 (13.0)
<65 y, n (%) 1217 (33.2) 804 (32.9)
65e74 y, n (%) 1031 (28.2) 655 (26.8)
75 y, n (%) 1414 (38.6) 988 (40.3)
CHADS2 score, mean (SD) 1.4 (1.2) 1.4 (1.1)
CHA2DS2-VASc score, mean (SD) 2.8 (1.7) 2.8 (1.6)
HAS-BLED score, mean (SD) 2.0 (1.1) 2.0 (1.1)
Female, n (%) 1667 (45.5) 1147 (46.9)
Comorbidities, n (%)
Hypertension 1908 (52.1) 1309 (53.5)
Heart failure 661 (18.1) 425 (17.4)
Ischemic heart disease 1002 (27.4) 695 (28.4)
Dyslipidemia 709 (19.4) 461 (18.8)
Diabetes 762 (20.8) 509 (20.8)
Hyperthyroidism 114 (3.1) 75 (3.1)
Sick sinus syndrome 174 (4.8) 117 (4.8)
Hypertrophic cardiomyopathy 19 (0.5) 9 (0.4)
Peripheral vascular disease 59 (1.6) 42 (1.7)
Stroke/TIA/TE 266 (7.3) 126 (5.2)
Cancer 343 (9.4) 255 (10.4)
Hepatic disease 140 (3.8) 108 (4.4)
Renal disease 242 (6.6) 196 (8.0)
Peptic ulcer disease 177 (4.8) 113 (4.6)
Thrombocytopenia 9 (0.3) 6 (0.3)
Bleeding history 256 (7.0) 188 (7.7)
Dementia 89 (2.4) 62 (2.5)
Psychiatric disease 4 (0.1) 4 (0.2)
Concomitant medications, n (%)
Antihypertensive agents 3109 (84.9) 2027 (82.8)
Antidyslipidemic agents 677 (18.5) 424 (17.3)
Antidiabetic agents 697 (19.0) 445 (18.2)
Medications associated with
increased bleeding tendency
1463 (40.0) 972 (39.7)
Medications associated with
decreased bleeding tendency
865 (23.6) 548 (22.4)
Aspirin 1629 (44.5) 1100 (45.0)
Clopidogrel 368 (10.1) 249 (10.2)
CHADS2 scoreZ congestive heart failure, hypertension, age 75 years
or TE (thromboembolism) score; CHA2DS2-VASc score Z congestive
mellitus, prior stroke or TIA or TE (doubled), vascular disease, a
score Z hypertension, abnormal renal/liver function, stroke, bleedi
ratio), elderly, drugs/alcohol (concomitant use); NA Z not availa
SD Z standard deviation.
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To compare baseline characteristics between groups, t test
or analysis of variance (ANOVA) was used for continuous
variables, whereas chi-square test was used for categorical
variables. Two multivariate logistic regression models were
used to examine the factors driving the initiation of anti-
coagulants and the selection of different anticoagulants.
No anticoagulant treatment and warfarin usage served as a
reference group in each model where factors driving thent Anticoagulant
treatment
(n Z 1215)
p Warfarin
(n Z 928)
NOACs
(n Z 287)
p
69.1 (12.3) 0.01 67.1 (12.4) 75.7 (9.5) <0.01
413 (34.0) <0.01 379 (40.8) 34 (11.9) <0.01
376 (31.0) 285 (30.7) 91 (31.7)
426 (35.0) 264 (28.5) 162 (56.5)
1.5 (1.2) 0.19 1.4 (1.2) 1.8 (1.1) <0.01
2.8 (1.7) 0.60 2.6 (1.7) 3.5 (1.5) <0.01
1.9 (1.1) 0.03 1.8 (1.2) 2.3 (1.0) <0.01
520 (42.8) 0.02 386 (41.6) 134 (46.7) 0.13
599 (49.3) 0.02 435 (46.9) 164 (57.1) <0.01
236 (19.4) 0.13 178 (19.2) 58 (20.2) 0.70
307 (25.3) 0.04 207 (22.3) 100 (34.8) <0.01
248 (20.4) 0.26 176 (19.0) 72 (25.1) 0.02
253 (20.8) 0.99 172 (18.5) 81 (28.2) <0.01
39 (3.2) 0.81 33 (3.6) 6 (2.1) 0.22
57 (4.7) 0.90 37 (4.0) 20 (7.0) 0.04
10 (0.8) 0.07 5 (0.5) 5 (1.7) 0.06
17 (1.4) 0.47 7 (0.8) 10 (3.5) <0.01
140 (11.5) <0.01 112 (12.1) 28 (9.8) 0.28
88 (7.2) <0.01 54 (5.8) 34 (11.9) <0.01
32 (2.6) 0.01 27 (2.9) 5 (1.7) 0.28
46 (3.8) <0.01 41 (4.4) 5 (1.7) 0.04
64 (5.3) 0.39 41 (4.4) 23 (8.0) 0.02
3 (0.3) 0.99 1 (0.1) 2 (0.7) 0.14
68 (5.6) 0.02 45 (4.9) 23 (8.0) 0.04
27 (2.2) 0.56 13 (1.4) 14 (4.9) <0.01
0 (0.0) 0.31 0 (0.0) 0 (0.0) NA
1082 (89.1) <0.01 813 (87.6) 269 (93.7) <0.01
253 (20.8) 0.01 185 (19.9) 68 (23.7) 0.17
252 (20.7) 0.06 182 (19.6) 70 (24.4) 0.08
491 (40.4) 0.69 370 (39.9) 121 (42.2) 0.49
317 (26.1) 0.01 241 (26.0) 76 (26.5) 0.86
529 (43.5) 0.42 377 (40.6) 152 (53.0) <0.01
119 (9.8) 0.72 86 (9.3) 33 (11.5) 0.27
, diabetes mellitus, prior stroke or TIA (transient ischemic attack)
heart failure, hypertension, age 75 years (doubled), diabetes
ge 65e74 years, sex category point score systems; HAS-BLED
ng history or predisposition, labile INR (international normalized
ble; NOACs Z non-vitamin K antagonist oral anticoagulants;
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Factors were reported as odds ratio (OR) with 95% confi-
dence intervals (CIs). CochraneArmitage test was used to
examine the trend for warfarin and dabigatran users over
2013. A p value <0.05 was considered statistically signifi-
cant. We performed all the analyses using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA).Results
Study population
There were 3662 nonvalvular AF patients recruited in the
study. Patient demographics are shown in Table 1. The
average age was 69 years; 38.6% of patients were
75 years old and 45.5% were female. In the study popu-
lation, hypertension was the most common comorbidity
(52.1%), and 27.4% had ischemic heart disease, 20.8% had
diabetes, and 19.2% had dyslipidemia. Of the 3662Dabigatr
After
65
Warfarin 76.4% (928/1215)
After the era of NOACs
27.2% (107/394)
Newly diagnosed patients with at least thr
codes from 1 January 2007 to 31 Dec
Exclusion:
No age record (N=
Under 20 years of
Presence of valvul
Hip or knee replac
History of pulmon
No anticoagulant treatment 
66.8% (2447/3662)
After the era of NOACs 46.2% (338/732)
Non-valvular atrial fibrill
After the era of N
After
Figure 1 Patient enrollmen
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patients with atrial fibrillation, Journal of the Formosan Medical Assononvalvular AF patients, 33.2% were anticoagulant users
whereas 53.8% were anticoagulant users after the era of
NOACs. Among anticoagulant users, 66.4% and 27.2% were
on NOACs and warfarin, respectively, after the era of
NOACs (Figure 1). The average CHADS2 score [standard
deviation (SD)], CHA2DS2-VASc score, and HAS-BLED score
were 1.4 (SDZ 1.2), 2.8 (1.7), and 2.0 (1.1), respectively.
Patients with no anticoagulant treatment generally were
older (40.3% were older than 75 years) compared to anti-
coagulant users. Patients with first prescription of NOACs
were older (56.5% were older than 75 years) compared to
warfarin (40.8% were younger than 65 years). There were
similar CHA2DS2-VASc score and HAS-BLED score between
the no anticoagulant treatment group and the anticoagu-
lant treatment group. Higher CHA2DS2-VASc score and HAS-
BLED score were found in the NOACs group compared to
the warfarin group (mean CHA2DS2-VASc score 3.5 in
NOACs vs. 2.6 in warfarin, p < 0.01; mean HAS-BLED score
2.3 in NOACs vs. 1.8 in warfarin, p < 0.01) (Figure 2). In
comparison, there were more patients with hypertensionan 21.3% (259/1215)
the era of NOACs
.7% (259/394)
Rivaroxaban 2.3% (28/1215)
After the era of NOACs
0.7% (28/394)
ee atrial fibrillation disease
ember 2013 (N=3968)
6)
age (N=25)
ar atrial fibrillation (N=252)
ement (N=2)
ary embolism or deep vein thrombosis (N=21)
ation patients (N=3662)
OACs (N=732)
Anticoagulant treatment
33.2% (1215/3662)
the era of NOACs 53.8% (394/732)
t flowchart for the study.
se of warfarin and non-vitamin K antagonist oral anticoagulants in
ciation (2016), http://dx.doi.org/10.1016/j.jfma.2016.05.007
Figure 2 Distribution of CHA2DS2-VASc score and HAS-BLED score in atrial fibrillation patients with different anticoagulants. (A)
Distribution of CHA2DS2-VASc score. (B) Distribution of HAS-BLED score. CHA2DS2-VASc Z for congestive heart failure, hyper-
tension, age 75 years, diabetes mellitus, prior stroke or TIA or TE, vascular disease, age 65e74 years, sex category (i.e., female
sex) point score systems; HAS-BLED Z hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition,
labile INR, elderly (age, older than 65 years), concomitant use of drugs or alcohol.
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coagulant treatment group (53.5% vs. 49.3%, p Z 0.02).
There were more patients with ischemic heart disease in
the no anticoagulant treatment group than in the antico-
agulant treatment group (28.4% vs. 25.3%, p Z 0.04). ThePlease cite this article in press as: Hu M-M, et al., Factors driving the u
patients with atrial fibrillation, Journal of the Formosan Medical Assopercentage of patients with stroke/TE/TIA history in the
anticoagulant treatment group was 2.2-fold higher than
that in the no anticoagulant treatment group (11.5% vs.
5.2%, p < 0.01). On the contrary, there were more patients
with a history of cancer, hepatic disease, renal disease,se of warfarin and non-vitamin K antagonist oral anticoagulants in
ciation (2016), http://dx.doi.org/10.1016/j.jfma.2016.05.007
Figure 3 First anticoagulant prescription trend in 2013. CochraneArmitage test for trends of warfarin versus dabigatran use:
p < 0.01. OAC Z oral anticoagulation.
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+ MODELand bleeding events in the no anticoagulant treatment
group (cancer: 10.4% vs. 7.2%, p < 0.01; hepatic disease:
4.4% vs. 2.6%, p Z 0.01; renal disease: 8.0% vs. 3.8%,
p < 0.01; bleeding history: 7.7% vs. 5.6%, p < 0.02). There
were more patients with hypertension, ischemic heart
disease, diabetes, and peripheral vascular disease in the
NOACs group than in the warfarin group (p < 0.01 for all
comorbidities listed above). A higher percentage of he-
patic and renal diseases (hepatic disease: 2.9% vs. 1.7%;
renal disease: 4.4% vs. 1.7%) and a lower percentage of
bleeding history (4.9% vs. 8.0%) were noted in the warfarin
group compared to the NOACs group. There was more
frequent aspirin and clopidogrel use in the no anticoagu-
lant treatment and NOACs group than in the anticoagulant
and warfarin group.
First anticoagulant prescription trend in 2013
Trends for first anticoagulant prescription after February 1,
2013 showed increased dabigatran use (Figure 3). The
percentage of dabigatran as first anticoagulant use in each
month reached its peak 1 month after the introduction of
dabigatran in the NTUH (91.5% in March 2013), followed by
a slow decline until December 2013 (43.9%). The percent-
age of warfarin prescription kept trending down from 100%
in February 2013 to 12.2% in December 2013. The decrease
in warfarin use was mainly reflected by increased dabiga-
tran use (p < 0.01 for trends of warfarin vs. dabigatran
use).
Factors driving the initiation of anticoagulants
Adjustment for age, sex (male as reference group),
comorbidities, concomitant medications, aspirin and clo-
pidogrel use was made in the multivariate logistic regres-
sion models. The result for factors driving the initiation ofPlease cite this article in press as: Hu M-M, et al., Factors driving the u
patients with atrial fibrillation, Journal of the Formosan Medical Assoanticoagulant therapy is listed in Table 2. Female sex, hy-
pertension, ischemic heart disease, cancer, hepatic dis-
ease, renal disease, bleeding history, and aspirin use were
the negative predictors for anticoagulant usage. Among
these predictors, hepatic disease (OR Z 0.57; 95% CI,
0.38e0.86) and renal disease (OR Z 0.43; 95% CI,
0.31e0.60) showed stronger negative association than
others. Stroke/TE/TIA history, use of antihypertensive
agents, use of antidiabetic agents, and medications asso-
ciated with decreased bleeding tendency were positive
predictors for anticoagulant use. Stroke/TE/TIA history was
the strongest positive predictor (OR Z 2.64; 95% CI,
2.02e3.45). After the era of NOACs, renal disease, bleeding
history, and clopidogrel use were the negative predictors
for anticoagulant use. Older age, peptic ulcer disease, and
antihypertensive agents use were positive predictors for
anticoagulant use.
Factors driving the selection of NOACs versus
warfarin
After adjustment, predictors for the selection of NOACs
versus warfarin are listed in Table 3. After the era of
NOACs, older age (ORZ 1.07; 95% CI, 1.04e1.10), ischemic
heart disease (OR Z 2.44; 95% CI, 1.21e4.92), antihyper-
tensive agents use (OR Z 2.76; 95% CI, 1.19e6.44), and
aspirin use (OR Z 1.93; 95% CI, 1.11e3.36) were the posi-
tive predictors associated with NOACs use. Hepatic disease
(OR Z 0.09; 95% CI, 0.02e0.42) was the positive predictor
associated with warfarin usage.Discussion
There were several major findings in our study. In factors
driving the initiation of anticoagulant therapy, we foundse of warfarin and non-vitamin K antagonist oral anticoagulants in
ciation (2016), http://dx.doi.org/10.1016/j.jfma.2016.05.007
Table 2 Factors driving the initiation of anticoagulants.
Variables Odds ratio (95% CI) After the era of NOACs
Odds ratio (95% CI)
Age 0.99 (0.98e1.00) 1.02 (1.00e1.03)*
Sex (female) 0.81 (0.70e0.94)* 0.84 (0.61e1.17)
Hypertension 0.82 (0.70e0.96)* 1.09 (0.77e1.53)
Heart failure 1.14 (0.95e1.37) 1.21 (0.81e1.82)
Ischemic heart disease 0.83 (0.69e0.99)* 1.05 (0.71e1.56)
Dyslipidemia 1.09 (0.87e1.37) 1.08 (0.67e1.76)
Diabetes 0.83 (0.63e1.09) 1.01 (0.57e1.82)
Hypertrophic cardiomyopathy 2.07 (0.82e5.22) 7.35 (0.78e69.51)
Hyperthyroidism 0.98 (0.65e1.48) 1.01 (0.41e2.49)
Peripheral vascular disease 0.78 (0.43e1.41) 0.54 (0.19e1.50)
Sick sinus syndrome 1.13 (0.81e1.58) 0.71 (0.37e1.36)
Cancer 0.61 (0.47e0.80)* 0.68 (0.40e1.14)
Hepatic disease 0.57 (0.38e0.86)* 0.54 (0.22e1.34)
Renal disease 0.43 (0.31e0.60)* 0.19 (0.09e0.41)*
Peptic ulcer disease 1.22 (0.87e1.71) 3.16 (1.36e7.34)*
Thrombocytopenia 1.06 (0.26e4.38) 1.40 (0.22e9.01)
Bleeding history 0.67 (0.49e0.92)* 0.54 (0.30e0.95)*
Dementia 0.83 (0.51e1.34) 1.86 (0.66e5.22)
Psychiatric disease NA (NA) NA (NA)
Stroke/TIA/TE 2.64 (2.02e3.45)* 1.64 (0.91e2.95)
Antihypertensive agents usage 1.94 (1.55e2.44)* 2.27 (1.41e3.64)*
Antidyslipidemic agents usage 1.19 (0.94e1.50) 1.27 (0.75e2.15)
Antidiabetic agents usage 1.37 (1.03e1.82)* 1.06 (0.57e1.97)
Medications with increased bleeding tendency 1.02 (0.86e1.21) 1.05 (0.72e1.54)
Medications with decreased bleeding tendency 1.25 (1.03e1.50)* 1.11 (0.75e1.64)
Aspirin usage 0.82 (0.70e0.95)* 1.35 (0.96e1.89)
Clopidogrel usage 0.89 (0.68e1.17) 0.54 (0.30e0.99)*
Medications associated with increased bleeding tendency, indicates anticancer agents with bleeding risk, anticoagulants except for
warfarin and NOACs, antiplatelets, NSAID, fibrinolytic agents, steroids, ginkgo, pentoxifylline, piracetam. Medications associated with
decreased bleeding tendency, indicates coagulation factors, tranexamic acid, H2 blocker, proton pump inhibitors, vitamin K.
* Statistically significant.
CI Z confidence interval; NA Z not available; NOACs Z non-vitamin K antagonist oral anticoagulants; NSAID Z nonsteroidal anti-
inflammatory drug; TE Z thromboembolism; TIA Z transient ischemic attack.
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anticoagulant use. The result can be supported by the
recommendation of using these agents as secondary pre-
vention for stroke in current treatment guidelines.11,12
However, up to 5.2% of patients with stroke/TE/TIA his-
tory were found in the no anticoagulant treatment group.
Judgment for benefit (stroke prevention) and risk
(bleeding) prior to the initiation of anticoagulant therapy is
the key. In our study, there was a comparable stroke risk
between the anticoagulant treatment group versus the no
anticoagulant treatment group according to CHADS2 score
and CHA2DS2-VASc score, whereas a higher HAS-BLED score
was noted in the no anticoagulant treatment group, which
showed bleeding risk as a major concern prior to initiating
anticoagulants. For AF patients with acute coronary syn-
drome, dual antiplatelet therapy plus anticoagulant treat-
ment may result in increased bleeding risk. The
combination of these agents still remains to be a dilemma
in clinical practice.15 In our study, comorbidities related to
increase bleeding risk were the negative predictors for
anticoagulant usage. This was not only illustrated in thePlease cite this article in press as: Hu M-M, et al., Factors driving the u
patients with atrial fibrillation, Journal of the Formosan Medical Assopatient demographics between the two groups but is also
consistent with the findings of Lin et al.5
As for the factors driving the selection of NOACs versus
warfarin, we found that more physicians were willing to
prescribe NOACs for patients as first anticoagulant pre-
scription. Generally, increased uptake of dabigatran and
decreased warfarin prescription were observed. However,
there were fluctuations on the curve for warfarin and
dabigatran prescription. This may be related to the patient
characteristics each month, patient preference, side effect
profile, and physicians’ experience with the medication.
Moreover, we found that older age, ischemic heart disease,
antihypertensive agents use, and aspirin use were the
positive predictors associated with NOACs use, whereas
hepatic disease was a positive predictor associated with
warfarin use after the era of NOACs. Of note, majority
(98.9%) of NOACs users were under the coverage of the NHI
program, and 90% were dabigatran users during the study
period. Adherence with the NHI prescribing recommenda-
tions for dabigatran in Taiwan is cited as the reason why
older age and ischemic heart disease were found as positivese of warfarin and non-vitamin K antagonist oral anticoagulants in
ciation (2016), http://dx.doi.org/10.1016/j.jfma.2016.05.007
Table 3 Factors driving the selection of NOACs versus
warfarin.
Variables After the era of NOACs
Odds ratio (95% CI)
Age 1.07 (1.04e1.10)*
Sex (female) 1.09 (0.63e1.87)
Hypertension 0.79 (0.44e1.42)
Heart failure 0.78 (0.41e1.49)
Ischemic heart disease 2.44 (1.21e4.92)*
Dyslipidemia 0.63 (0.29e1.37)
Diabetes 1.45 (0.51e4.13)
Hypertrophic cardiomyopathy 1.35 (0.16e11.72)
Hyperthyroidism 0.54 (0.13e2.20)
Peripheral vascular disease NA (NA)
Sick sinus syndrome 2.09 (0.52e8.39)
Cancer 2.46 (0.86e7.02)
Hepatic disease 0.09 (0.02e0.42)*
Renal disease 0.30 (0.07e1.29)
Peptic ulcer disease 4.26 (0.90e20.10)
Thrombocytopenia 0.60 (0.04e8.57)
Bleeding history 0.78 (0.28e2.21)
Dementia 2.07 (0.40e10.78)
Psychiatric disease NA (NA)
Stroke/TIA/TE 0.58 (0.25e1.37)
Antihypertensive agents usage 2.76 (1.19e6.44)*
Antidyslipidemic agents usage 1.08 (0.47e2.49)
Antidiabetic agents usage 0.68 (0.24e1.94)
Medications with increased
bleeding tendency
1.09 (0.59e2.03)
Medications with decreased
bleeding tendency
0.59 (0.31e1.11)
Aspirin usage 1.93 (1.11e3.36)*
Clopidogrel usage 0.76 (0.27e2.16)
Medications associated with increased bleeding tendency, in-
dicates anticancer agents with bleeding risk, anticoagulants
except for warfarin and NOACs, antiplatelets, NSAID, fibrino-
lytic agents, steroids, ginkgo, pentoxifylline, piracetam. Medi-
cations associated with decreased bleeding tendency, indicates
coagulation factors, tranexamic acid, H2 blocker, proton pump
inhibitors, vitamin K.
* Statistically significant.
CI Z confidence interval; NA Z not available; NOACs Z non-
vitamin K antagonist oral anticoagulants; NSAIDZ nonsteroidal
anti-inflammatory drug; TE Z thromboembolism;
TIA Z transient ischemic attack.
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NOACs use after the era of NOACs. Aspirin use was a posi-
tive predictor for NOACs usage. This may be explained by
the higher percentage of patients with ischemic heart dis-
ease in the NOACs group. However, concomitant use of
aspirin and anticoagulant (regardless of whether warfarin
or NOAC was used) leads to higher bleeding risk for pa-
tients, and, to our knowledge, there is no sufficient evi-
dence guiding the combination use of NOACs and
antiplatelet agents so far. Our finding requires further
confirmation in future studies. Although NOACs are knownPlease cite this article in press as: Hu M-M, et al., Factors driving the u
patients with atrial fibrillation, Journal of the Formosan Medical Assofor less foodedrug interactions and do not require frequent
blood testing, there is no sufficient evidence supporting the
use of NOACs in patients with renal dysfunction and hepatic
dysfunction so far. When it comes to therapeutic drug
monitoring for warfarin, the INR is a good response marker
for effectiveness and safety. More safety information
regarding the use for NOACs should be provided in future
studies.
To our knowledge, this is the first study in Taiwan to
explore the factors driving the initiation and selection of
anticoagulants. However, there are several limitations in
our study. First, our results were obtained from a single
medical center experience. However, it should be noted
that the latest NHI database was not available during the
time when we performed the study. Up to 98.9% of NOACs
users were under the coverage of the NHI program, making
our results more generalizable to the whole Taiwanese
population. Second, the recruitment of patients was based
on ICD-9-CM codes for AF owing to the lack of electrocar-
diogram results. We used at least three AF disease codes
present in the electronic database as inclusion criteria,
which is a stricter requirement compared with previous AF
studies performed using the NHIRD.5,16,17 Finally, other
factors driving the initiation of warfarin and NOACs,
including patient preference and adherence, were not
available in our study. This type of information requires
other study designs (e.g., chart review and questionnaire)
to provide further results.
In our study, we have shown the real-world practice of
anticoagulants and NOACs usage in patients with AF and
factors driving the initiation of anticoagulants/selection of
NOACs versus warfarin. These real-world data are a useful
tool to monitor the adherence to the guideline-
recommended anticoagulants and NOACs usage in patients
with AF, and further strategies to improve the clinical
practice can be implemented according to these results.
Conclusion
Our study provides the factors driving the initiation of
anticoagulant treatment and the selection of different
anticoagulants in NTUH. Among the patients who initiated
anticoagulant treatment, 66.4% used NOACs instead of
warfarin after the era of NOACs. Stroke history was asso-
ciated with anticoagulant use, whereas comorbidities were
associated with increased bleeding risk, showing opposite
results. Patients with hepatic diseases were less likely to
use NOACs. During the study period, the prescription rate of
NOACs increased, and in warfarin users we found the
opposite trend.
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Appendix 1. ICD-9-CM codes used for defining comorbidities.
Comorbidities ICD-9-CM code
Atrial fibrillation 427.31
Hypertension 401.xx, 402.xx, 403.xx, 404.xx, 405.xx
Heart failure 428.xx
Ischemic heart disease 410.xx, 411.xx, 412.xx, 413.xx, 414.xx
Dyslipidemia 272.xx
Diabetes 250.xx
Hyperthyroidism 242.xx
Sick sinus syndrome 427.81
Hypertrophic cardiomyopathy 425.1x
Peripheral vascular disease 443.xx
Ischemic stroke/ Ischemic stroke: 433.xx, 434.xx
Transient ischemic attack (TIA)/ TIA: 435.xx
Thromboembolism (TE) TE: 453.xx, 415.xx
Cancer 140.xxw208.xx
Hepatic disease 570.xxw573.xx
Renal disease 580.xxw589.xx
Peptic ulcer disease 531.xxw534.xx
Thrombocytopenia 287.5
Rheumatic heart disease 393.xxw398.xx
Bleeding history Definite bleeding:
531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x,
533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 535.01, 535.11, 535.21, 535.31,
535.41, 535.51, 535.61, 537.83, 456.0, 456.20, 530.7, 530.82, 578.0, 455.2, 455.5,
455.8, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578.1, 578.9, 593.81,
599.7, 623.8, 626.2, 626.6, 430, 431, 432, 432.0, 432.1, 432.9, 852.0, 852.2, 852.4,
853.0, 423.0, 459.0, 568.81, 719.1x, 784.7, 784.8, 786.3
Critical site bleeding:
430, 431, 432, 852.0, 852.2, 852.4, 853.0, 336.1, 363.6, 372.72, 376.32, 377.42, 379.23,
719.1, 729.92, 729.97, 423.0, 593.81, 772.5, 866.01, 866.02, 866.11, 866.12
Dementia 290.xx
Psychiatric disease 295.xx
Note. The ICD-9-CM codes for bleeding history in our study were adapted from “An automated database definition for serious bleeding
due to oral anticoagulant use,” by A.W. Cunningham, C.M. Stein, C.P. Chung, J.R. Daugherty, W.E. Smalley, W.A. Ray, 2011, Pharma-
coepidemiol Drug Saf, 20, p. 560e66. Copyright 2016 by John Wiley and Sons. Adapted with permission.
ICD-9-CM Z International Classification of Diseases, Ninth Revision, Clinical Modification.
Appendix 2. Codes used for defining surgeries.
Codes for surgery orders Codes for physician orders
Knee replacement 64164B00
Hip replacement 64162B00
Valve repair 68015B00 68029BZS 68029B0S
20360207 69033B00 20360204
20360206 68029B00
Valve replacement 68016A00 20360144 20360150 68017B00 20360130 20360300
20360143 20360142 20360148 20360131 20360111
20360139 20360113 68016B00 20360141 20360304
20360146 20360112 20360303 20360147 20360302
20360110 20360114 68018B00 20360149
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Appendix 3. Generic names for concomitant medications.
Medication Generic names
Antihypertensive agents
ACEI Captopril
Enalapril
Lisinopril
Ramipril
Benazepril
Cilazapril
Fosinopril
Imidapril
ARB Losartan
Valsartan
Irbesartan
Candesartan
Telmisartan
Olmesartan
Azilsartan
Beta blocker Metoprolol
Atenolol
Esmolol
Propranolol
Nadolol
Carvedilol
Bisoprolol
Sotalol
Carteolol
Acebutolol
Betaxolol
Labetalol
DHP-CCB Amlodipine
Felodipine
Isradipine
Nicardipine
Nifedipine
Nimodipine
Barnidipine
Lercanidipine
Non-DHP-CCB Diltiazem Verapamil
Diuretics Acetazolamide
Trichlormethiazide
Indapamide
Furosemide
Bumetanide
Spironolactone
Eplerenone
Aliskiren Aliskiren
Antidyslipidemic agents
Ezetimibe Ezetimibe
Fibrate Bezafibrate Gemfibrozil Fenofibrate
Statin Simvastatin
Lovastatin
Pravastatin
Fluvastatin
Atorvastatin
Rosuvastatin
Pitavastatin
Antidiabetic agents
Sulfonylurea Glibenclamide
(glyburide)
Glipizide
Gliquidone
Gliclazide
Glimepiride
Meglitinide Repaglinide Nateglinide
a-Glucosidase inhibitor Acarbose
Biguanide Metformin
TZD Rosiglitazone Pioglitazone
DPP-4 inhibitor Sitagliptin Vildagliptin Saxagliptin Linagliptin
Insulin Insulin lispro
Insulin aspart
Insulin glulisine
Regular insulin
NPH
Lente insulin
Ultralente insulin
Insulin glargine
Insulin detemir
regular
30% þ NPH 70%
Medications associated with increased bleeding tendency
Anticancer agents with bleeding
risk
Azathioprine
Cyclophosphamide
Carboplatin
Cytarabine
Pemetrexed
5-FU (5-fluorouracil)
Hydroxyurea
6-MP (mercaptopurine)
Vinblastine
MTX
(methotrexate)
Imatinib
Dasatinib
Nilotinib
Sorafenib
Sunitinib
Bevacizumab
Anticoagulants (except for
warfarin, dabigatran,
rivaroxaban)
Dalteparin Enoxaparin Heparin
Antiplatelets (except for aspirin) Clopidogrel
Ticlopidine
Ticagrelor
Dipyridamole
Eptifibatide
Tirofiban
Cilostazol
Anagrelide
Iloprost
Sulfinpyrazone
NSAID Diclofenac
Etodolac
Ibuprofen
Indomethacin
Meclofenamate
Meloxicam
Nabumetone
Naproxen
Piroxicam
Sulindac
Tiaprofenic acid
Ketorolac
Acemetacin
Celecoxib
Rofecoxib
Etoricoxib
Sulindac
Tenoxicam
Tiaprofenic acid
Fibrinolytic agents Streptokinase Urokinase
Steroids Betamethasone
Cortisone
Dexamethasone
Fludrocortisone
Hydrocortisone
Methylprednisolone
Prednisolone
Triamcinolone
Ginkgo, Pentoxifylline, Piracetam Ginkgo, pentoxifylline, piracetam
Medications associated with decreased bleeding tendency
Coagulation factor Factor IX Complex,
factors II, VII, IX, X, PCC
Anti-inhibitorecoagulant
complex (factors II, VIIa, IX, X)
Plasma protein
fraction
Coagulation
factor VIIa
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(continued )
Medication Generic names
Tranexamic acid Tranexamic acid
H2 blocker Cimetidine
Ranitidine
Famotidine Nizatidine Roxatidine
PPI Omeprazole
Pantoprazole
Lansoprazole
Rabeprazole
Esomeprazole Dexlansoprazole
Vitamin K Vitamin K
ACEI Z angiotensin-converting enzyme inhibitors; ARB Z angiotensin receptor blocker; DHP-CCB Z dihydropyridine calcium channel
blocker; DPP-4 inhibitor Z dipeptidyl peptidase-4 inhibitor; H2 blocker Z histamine type 2 receptor blocker; non-DHP-
CCB Z nondihydropyridine calcium channel blocker; NSAID Z nonsteroidal anti-inflammatory drug; PPI Z proton pump inhibitor;
TZD Z thiazolidinedione.
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